PL4496795T3 - Związki indazolowe podstawione piperazyną jako inhibitory parg - Google Patents
Związki indazolowe podstawione piperazyną jako inhibitory pargInfo
- Publication number
- PL4496795T3 PL4496795T3 PL23718143.3T PL23718143T PL4496795T3 PL 4496795 T3 PL4496795 T3 PL 4496795T3 PL 23718143 T PL23718143 T PL 23718143T PL 4496795 T3 PL4496795 T3 PL 4496795T3
- Authority
- PL
- Poland
- Prior art keywords
- parg
- inhibitors
- indazole compounds
- substituted indazole
- piperazine substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263322994P | 2022-03-23 | 2022-03-23 | |
| PCT/US2023/064825 WO2023183850A1 (en) | 2022-03-23 | 2023-03-22 | Piperazine substituted indazole compounds as inhibitors of parg |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4496795T3 true PL4496795T3 (pl) | 2026-07-20 |
Family
ID=86053625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL23718143.3T PL4496795T3 (pl) | 2022-03-23 | 2023-03-22 | Związki indazolowe podstawione piperazyną jako inhibitory parg |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US12269820B2 (pl) |
| EP (2) | EP4496795B1 (pl) |
| JP (1) | JP7783436B2 (pl) |
| KR (1) | KR20240165402A (pl) |
| CN (1) | CN119255994A (pl) |
| AR (1) | AR128846A1 (pl) |
| AU (1) | AU2023239344A1 (pl) |
| CA (1) | CA3245542A1 (pl) |
| CL (1) | CL2024002805A1 (pl) |
| CO (1) | CO2024012798A2 (pl) |
| CR (1) | CR20240391A (pl) |
| DK (1) | DK4496795T3 (pl) |
| DO (1) | DOP2024000187A (pl) |
| ES (1) | ES3070012T3 (pl) |
| FI (1) | FI4496795T3 (pl) |
| HR (1) | HRP20260714T1 (pl) |
| IL (1) | IL315722A (pl) |
| LT (1) | LT4496795T (pl) |
| MA (1) | MA69135B1 (pl) |
| MX (1) | MX2024011545A (pl) |
| PE (1) | PE20251690A1 (pl) |
| PL (1) | PL4496795T3 (pl) |
| PT (1) | PT4496795T (pl) |
| RS (1) | RS68230B1 (pl) |
| SM (1) | SMT202600201T1 (pl) |
| TW (1) | TW202345809A (pl) |
| WO (1) | WO2023183850A1 (pl) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| IL291436B1 (en) * | 2019-09-20 | 2026-07-01 | Ideaya Biosciences Inc | History of indole and indazole sulfonamido 4-mutates as PARG inhibitors |
| PL4496795T3 (pl) | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
| AU2024253809A1 (en) * | 2023-04-05 | 2025-10-16 | Ideaya Biosciences, Inc. | Combination therapy comprising a parg inhibitor and a topoisomerase inhibitor for treating cancer |
| WO2025046148A1 (en) | 2023-09-01 | 2025-03-06 | Forx Therapeutics Ag | Novel parg inhibitors |
| TW202528308A (zh) * | 2023-09-20 | 2025-07-16 | 美商愛德亞生物科學公司 | Parg抑制劑 |
| WO2025064750A1 (en) * | 2023-09-20 | 2025-03-27 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025082231A1 (zh) * | 2023-10-20 | 2025-04-24 | 上海璎黎药业有限公司 | 一种杂芳环磺酰胺结构化合物、其药物组合物及应用 |
| WO2025087941A1 (en) | 2023-10-23 | 2025-05-01 | Universite De Geneve | Parg inhibitors in combination with parp inhibitors and uses thereof |
| CN122249439A (zh) | 2023-10-26 | 2026-06-19 | 上海齐鲁制药研究中心有限公司 | Parg抑制剂 |
| WO2026022150A1 (en) | 2024-07-22 | 2026-01-29 | Forx Therapeutics Ag | Parg inhibitory compounds |
| TW202610628A (zh) * | 2024-07-29 | 2026-03-16 | 大陸商海思科醫藥集團股份有限公司 | 磺醯胺化合物及其在醫藥上的應用 |
| WO2026032385A1 (zh) * | 2024-08-07 | 2026-02-12 | 上海亚虹医药科技有限公司 | 多聚adp核糖水解酶抑制剂及其医药用途 |
| WO2026062066A1 (en) | 2024-09-17 | 2026-03-26 | Forx Therapeutics Ag | Compounds inducing parg degradation |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1157858A (en) | 1979-12-03 | 1983-11-29 | Ikuo Ueda | Quinazoline derivatives |
| DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| US7009052B2 (en) | 2003-03-20 | 2006-03-07 | Warner Lambert Company Llc | Sulfonamide derivatives |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| TWI332003B (en) | 2004-01-30 | 2010-10-21 | Lilly Co Eli | Kinase inhibitors |
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| WO2005080399A1 (ja) | 2004-02-24 | 2005-09-01 | Japan Tobacco Inc. | ４環縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| WO2005092890A2 (en) | 2004-03-25 | 2005-10-06 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof |
| WO2007014226A2 (en) | 2005-07-26 | 2007-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds for the treatment of neurodegeneration and stroke |
| NZ568910A (en) | 2006-01-24 | 2011-04-29 | Lilly Co Eli | Indole sulfonamide modulators of progesterone receptors |
| WO2007107469A1 (en) | 2006-03-20 | 2007-09-27 | F. Hoffmann-La Roche Ag | Methods of inhibiting btk and syk protein kinases |
| WO2009047255A1 (en) | 2007-10-09 | 2009-04-16 | Ucb Pharma, S.A. | Heterobicyclic compounds as histamine h4-receptor antagonists |
| WO2009051815A1 (en) | 2007-10-19 | 2009-04-23 | Bipar Sciences, Inc. | Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors |
| RU2011105810A (ru) | 2008-07-17 | 2012-08-27 | Асахи Касеи Фарма Корпорейшн (Jp) | Азотсодержащие бициклические гетероциклические соединения |
| CN101429191B (zh) | 2008-11-03 | 2012-05-23 | 中国药科大学 | 取代的四氢异喹啉衍生物的用途 |
| CN102791131A (zh) | 2010-01-13 | 2012-11-21 | 葛兰素史密斯克莱有限责任公司 | 化合物和方法 |
| US8846935B2 (en) | 2010-05-07 | 2014-09-30 | Glaxosmithkline Llc | Indazoles |
| JP2013526484A (ja) | 2010-05-07 | 2013-06-24 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのアミノ‐キノリン |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP2627648A1 (en) | 2010-09-16 | 2013-08-21 | Novartis AG | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS |
| CA2817460A1 (en) | 2010-12-17 | 2012-06-21 | F. Hoffmann-La Roche Ag | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof |
| EP2471363A1 (de) | 2010-12-30 | 2012-07-04 | Bayer CropScience AG | Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen |
| JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
| WO2013027168A1 (en) | 2011-08-22 | 2013-02-28 | Pfizer Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
| WO2013067300A1 (en) | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| WO2014026327A1 (en) | 2012-08-15 | 2014-02-20 | Merck Sharp & Dohme Corp. | 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof |
| HK1217649A1 (zh) | 2012-12-27 | 2017-01-20 | 德雷克塞尔大学 | 針對hbv感染的新型抗病毒劑 |
| CN105980365B (zh) | 2014-02-11 | 2019-06-21 | 拜耳医药股份公司 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| MA41140A (fr) | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| RU2019117556A (ru) | 2016-11-18 | 2020-12-18 | Мерк Шарп И Доум Корп. | Индазольные производные, пригодные в качестве ингибиторов диацилглицерид o-ацилтрансферазы 2 |
| WO2020205646A2 (en) | 2019-03-29 | 2020-10-08 | Board Of Regents, The University Of Texas System | Small molecule parg inhibitors and methods of use thereof |
| IL291436B1 (en) | 2019-09-20 | 2026-07-01 | Ideaya Biosciences Inc | History of indole and indazole sulfonamido 4-mutates as PARG inhibitors |
| US20250002491A1 (en) | 2021-10-04 | 2025-01-02 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
| CA3225500A1 (en) | 2021-10-04 | 2023-04-13 | Ulrich Luecking | Parg inhibitory compounds |
| CA3251360A1 (en) | 2022-02-14 | 2023-08-17 | Arase Therapeutics Inc. | PARG INHIBITORS |
| US20230272485A1 (en) | 2022-02-16 | 2023-08-31 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| PL4496795T3 (pl) | 2022-03-23 | 2026-07-20 | Ideaya Biosciences, Inc. | Związki indazolowe podstawione piperazyną jako inhibitory parg |
| TWI878939B (zh) | 2022-06-29 | 2025-04-01 | 大陸商杭州聖域生物醫藥科技有限公司 | 五元並六元含氮化物、其中間體、製備方法和應用 |
| IL320031A (en) | 2022-10-03 | 2025-06-01 | Forx Therapeutics Ag | Parg inhibitory compound |
| EP4646208A1 (en) | 2023-01-06 | 2025-11-12 | Ideaya Biosciences, Inc. | Treatment of er+ breast cancer comprising homologous recombination deficiency using parg inhibitor |
| WO2024173524A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted benzimidazole compounds |
| WO2024173453A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted imidazopyridine compounds |
| WO2024173530A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Heteroaryl-substituted pyrazolo/imidazo pyridine compounds |
| WO2024173514A1 (en) | 2023-02-14 | 2024-08-22 | Ideaya Biosciences, Inc. | Amide and ester-substituted imidazopyridine compounds |
-
2023
- 2023-03-22 PL PL23718143.3T patent/PL4496795T3/pl unknown
- 2023-03-22 AU AU2023239344A patent/AU2023239344A1/en active Pending
- 2023-03-22 SM SM20260201T patent/SMT202600201T1/it unknown
- 2023-03-22 FI FIEP23718143.3T patent/FI4496795T3/fi active
- 2023-03-22 EP EP23718143.3A patent/EP4496795B1/en active Active
- 2023-03-22 ES ES23718143T patent/ES3070012T3/es active Active
- 2023-03-22 LT LTEPPCT/US2023/064825T patent/LT4496795T/lt unknown
- 2023-03-22 HR HRP20260714TT patent/HRP20260714T1/hr unknown
- 2023-03-22 AR ARP230100697A patent/AR128846A1/es unknown
- 2023-03-22 MX MX2024011545A patent/MX2024011545A/es unknown
- 2023-03-22 WO PCT/US2023/064825 patent/WO2023183850A1/en not_active Ceased
- 2023-03-22 US US18/188,278 patent/US12269820B2/en active Active
- 2023-03-22 MA MA69135A patent/MA69135B1/fr unknown
- 2023-03-22 PE PE2024002037A patent/PE20251690A1/es unknown
- 2023-03-22 IL IL315722A patent/IL315722A/en unknown
- 2023-03-22 PT PT237181433T patent/PT4496795T/pt unknown
- 2023-03-22 JP JP2024556141A patent/JP7783436B2/ja active Active
- 2023-03-22 KR KR1020247034606A patent/KR20240165402A/ko active Pending
- 2023-03-22 CA CA3245542A patent/CA3245542A1/en active Pending
- 2023-03-22 DK DK23718143.3T patent/DK4496795T3/da active
- 2023-03-22 RS RS20260643A patent/RS68230B1/en unknown
- 2023-03-22 CN CN202380042074.9A patent/CN119255994A/zh active Pending
- 2023-03-22 TW TW112110751A patent/TW202345809A/zh unknown
- 2023-03-22 CR CR20240391A patent/CR20240391A/es unknown
- 2023-03-22 EP EP26160129.8A patent/EP4775206A2/en active Pending
-
2024
- 2024-09-17 CL CL2024002805A patent/CL2024002805A1/es unknown
- 2024-09-20 CO CONC2024/0012798A patent/CO2024012798A2/es unknown
- 2024-09-20 DO DO2024000187A patent/DOP2024000187A/es unknown
-
2025
- 2025-02-28 US US19/066,791 patent/US20250376467A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023239344A1 (en) | 2024-10-10 |
| MX2024011545A (es) | 2024-09-26 |
| IL315722A (en) | 2024-11-01 |
| DOP2024000187A (es) | 2024-12-30 |
| CA3245542A1 (en) | 2023-09-28 |
| EP4496795B1 (en) | 2026-04-01 |
| MA69135B1 (fr) | 2026-07-31 |
| EP4496795A1 (en) | 2025-01-29 |
| CN119255994A (zh) | 2025-01-03 |
| DK4496795T3 (da) | 2026-05-04 |
| US20230303556A1 (en) | 2023-09-28 |
| EP4775206A2 (en) | 2026-07-15 |
| TW202345809A (zh) | 2023-12-01 |
| KR20240165402A (ko) | 2024-11-22 |
| CO2024012798A2 (es) | 2024-10-21 |
| FI4496795T3 (fi) | 2026-05-21 |
| CR20240391A (es) | 2024-11-05 |
| HRP20260714T1 (hr) | 2026-07-17 |
| US20250376467A1 (en) | 2025-12-11 |
| WO2023183850A1 (en) | 2023-09-28 |
| AR128846A1 (es) | 2024-06-19 |
| JP7783436B2 (ja) | 2025-12-09 |
| CL2024002805A1 (es) | 2025-05-09 |
| JP2025512780A (ja) | 2025-04-22 |
| SMT202600201T1 (it) | 2026-07-16 |
| PT4496795T (pt) | 2026-05-04 |
| RS68230B1 (en) | 2026-07-31 |
| US12269820B2 (en) | 2025-04-08 |
| ES3070012T3 (en) | 2026-06-11 |
| PE20251690A1 (es) | 2025-07-02 |
| LT4496795T (lt) | 2026-07-10 |